私たちは抗体の発現、開発、最適化に注力し、先進的な自動化生産ラインを持ち、競争力のある価格と効率的なリードタイムを提供できます。
私たちはECACCからライセンスされたCHOK1BN細胞株の商業化に関する排他的な再ライセンス権を保有しています。
私たちの1,500以上のグローバルなバイオテクノロジー企業や製薬企業とのパートナーシップになり、そして、国際的な臨床段階での共同の進歩と結びついています。
私たちは、お客様に提供した抗体の所有権を守り、機密情報の保持をお約束します。
This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#
Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.
We are excited to announce that Biointron will be participating in the upcoming BIO Asia - Taiwan Conference, set to take place from July 24 to 28, 2024, at the Taipei Nangang Exhibition Center. This prestigious event is a major gathering for the biotechnology and pharmaceutical industries, attracting professionals and companies from around the globe.
Biointron is thrilled to announce our participation in the Immuno-Oncology Summit 2024! Mark your calendars for August 7 - 9 and join us at Hilton Philadelphia at Penn's Landing, PA, for this premier event dedicated to the latest advancements in immuno-oncology.
We are delighted to announce that Biointron will be participating in the 15th Annual World Bispecific Summit, scheduled to take place from September 3 to 5, 2024, in Boston, Massachusetts. This summit is a cornerstone event for the bispecific antibody community, attracting thought leaders and industry experts worldwide to discuss the latest innovations and breakthroughs in bispecific therapeutics.
ScientistとScience Exchangeとのご利用可能です。
